<p>Viridian Therapeutics, Inc.（纳斯达克代码：VRDN - 获取免费报告）在周四创下了 52 周的新高，此前公司发布了超出预期的财报。该股最高交易价为 28.59 美元，最后交易价为 28.2170 美元，成交量为 1730401 股。该股票此前收盘价为 24.42 美元。</p>
<p>该公司报告本季度每股收益为（0.34 美元），超出市场共识预期的（0.82 美元）0.48 美元。Viridian Therapeutics 的净利润率为负 112,806.88%，股本回报率为负 78.95%。该公司本季度的收入为 70,000 美元，而分析师预期为 1621,000 美元。与去年同期相比，该公司的季度收入增长了 81,993.0%。</p>
<p>获取 <strong>Viridian Therapeutics</strong> 的提醒：</p>
<h2>分析师设定新目标价</h2>
<p>多位分析师最近对该公司进行了评论。高盛集团在周四的研究报告中重申了对 Viridian Therapeutics 股票的 “买入” 评级。Oppenheimer 在 10 月 21 日的研究报告中将 Viridian Therapeutics 的目标价从 32.00 美元上调至 36.00 美元，并给予该股票 “跑赢大盘” 的评级。Needham &amp; Company LLC 在 8 月 6 日的研究报告中将 Viridian Therapeutics 的目标价从 36.00 美元下调至 34.00 美元，并对该股票设定了 “买入” 评级。BTIG Research 在周二的研究报告中重新发布了 “买入” 评级，并对 Viridian Therapeutics 的股票设定了 61.00 美元的目标价。最后，Jefferies Financial Group 在 8 月 25 日的研究报告中开始覆盖 Viridian Therapeutics，给予 “买入” 评级和 44.00 美元的目标价。九位研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 38.22 美元。</p>
<p><strong>查看我们关于 Viridian Therapeutics 的最新研究报告</strong></p>
<h2>Viridian Therapeutics 的内部交易</h2>
<p>在其他消息中，董事 Fairmount Funds Management Llc 在 10 月 23 日的交易中购买了 454,545 股该股票。该股票的平均购买成本为每股 22.00 美元，总交易额为 9,999,990.00 美元。收购后，该董事持有公司 3,914,458 股股票，价值 86,118,076 美元。此次交易使其持股增加了 13.14%。该收购在向 SEC 的备案中披露，相关信息可通过此链接访问。1.58% 的股票由公司内部人士持有。</p>
<h2>机构投资者对 Viridian Therapeutics 的看法</h2>
<p>机构投资者最近对该公司的持仓进行了调整。Bessemer Group Inc.在第三季度将其在 Viridian Therapeutics 的持仓增加了 947.7%。Bessemer Group Inc.目前持有 2,085 股该公司的股票，价值 45,000 美元，此前在该期间又购买了 1,886 股。Principal Financial Group Inc.在第三季度将其在 Viridian Therapeutics 的持仓增加了 4.7%。Principal Financial Group Inc.目前持有 213,329 股该公司的股票，价值 4,604,000 美元，此前又购买了 9,493 股。AlphaQuest LLC 在第三季度将其在 Viridian Therapeutics 的持仓增加了 1,695.0%。AlphaQuest LLC 目前持有 17,645 股该公司的股票，价值 381,000 美元，此前在上个季度又收购了 16,662 股。Knights of Columbus Asset Advisors LLC 在第三季度将其在 Viridian Therapeutics 的持仓增加了 2.4%。Knights of Columbus Asset Advisors LLC 目前持有 59,410 股该公司的股票，价值 1,282,000 美元，此前在上个季度又收购了 1,386 股。最后，Y Intercept Hong Kong Ltd 在第三季度将其在 Viridian Therapeutics 的持仓增加了 430.3%。Y Intercept Hong Kong Ltd 目前持有 64,594 股该公司的股票，价值 1,394,000 美元，此前在上个季度又收购了 52,414 股。</p>
<h2>Viridian Therapeutics 股票表现</h2>
<p>该公司的 50 日移动平均线为 20.94 美元，200 日移动平均线为 17.34 美元。该股票的市值为 22.5 亿美元，市盈率为-7.37，贝塔值为 0.49。该公司的债务与股本比率为 0.04，速动比率为 11.01，流动比率为 11.01。</p>
<h2>关于 Viridian Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Viridian Therapeutics, Inc.是一家生物技术公司，致力于发现和开发严重和罕见疾病的治疗方案。该公司的产品管线包括 VRDN-001，一种针对类胰岛素生长因子-1 受体的单克隆抗体，目前正在进行治疗甲状腺眼病（TED）的三期临床试验；以及 VRDN-003，一种下一代 IGF-1R 人源化单克隆抗体，针对 IGF-1R 并结合半衰期延长技术用于治疗 TED。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 Viridian Therapeutics</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>Dutch Bros 连续第 11 个季度超预期盈利</li>
<li>投资汽车股票</li>
<li>从分红到增长：为什么这三只股票在 2025 年脱颖而出</li>
<li>投资者如何找到最佳的便宜分红股票</li>
<li>AMD 的价格回调意味着机会：大幅收益即将到来</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Viridian Therapeutics 吗？</h2>
<p>在考虑 Viridian Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Viridian Therapeutics 并不在名单上。</p>
<p>虽然 Viridian Therapeutics 目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

VRDN

<p>Viridian Therapeutics（纳斯达克代码：VRDN）在报告出乎意料的盈利后，达到了新的 12 个月高点 28.59 美元，每股收益（EPS）为（0.34 美元），而市场共识预期为（0.82 美元）。该股票收盘价为 28.2170 美元，较 24.42 美元上涨。分析师们设定了新的价格目标，Oppenheimer 将其目标上调至 36.00 美元，而 BTIG 则维持 61.00 美元的目标。机构投资者也显著增加了他们的持股比例。该公司专注于开发严重疾病的治疗方案，目前有针对甲状腺眼病的产品在临床试验中</p>

<p>Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) hit a new 52-week high on Thursday following a better than expected earnings announcement. The company traded as high as $28.59 and last traded at $28.2170, with a volume of 1730401 shares changing hands. The stock had previously closed at $24.42.</p>
<div class="lb-trans"><p>Viridian Therapeutics, Inc.（纳斯达克代码：VRDN - 获取免费报告）在周四创下了 52 周的新高，此前公司发布了超出预期的财报。该股最高交易价为 28.59 美元，最后交易价为 28.2170 美元，成交量为 1730401 股。该股票此前收盘价为 24.42 美元。</p>
</div><p>The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.48. Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $16.21 million. The business's revenue for the quarter was up 81993.0% compared to the same quarter last year.</p>
<div class="lb-trans"><p>该公司报告本季度每股收益为（0.34 美元），超出市场共识预期的（0.82 美元）0.48 美元。Viridian Therapeutics 的净利润率为负 112,806.88%，股本回报率为负 78.95%。该公司本季度的收入为 70,000 美元，而分析师预期为 1621,000 美元。与去年同期相比，该公司的季度收入增长了 81,993.0%。</p>
</div><p>Get <strong>Viridian Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Viridian Therapeutics</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of analysts recently commented on the company. The Goldman Sachs Group reaffirmed a &#34;buy&#34; rating on shares of Viridian Therapeutics in a research note on Thursday. Oppenheimer raised their price target on Viridian Therapeutics from $32.00 to $36.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, October 21st. Needham &amp; Company LLC decreased their price target on Viridian Therapeutics from $36.00 to $34.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, August 6th. BTIG Research reissued a &#34;buy&#34; rating and issued a $61.00 price target on shares of Viridian Therapeutics in a research note on Tuesday. Finally, Jefferies Financial Group started coverage on Viridian Therapeutics in a research note on Monday, August 25th. They issued a &#34;buy&#34; rating and a $44.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $38.22.</p>
<div class="lb-trans"><p>多位分析师最近对该公司进行了评论。高盛集团在周四的研究报告中重申了对 Viridian Therapeutics 股票的 “买入” 评级。Oppenheimer 在 10 月 21 日的研究报告中将 Viridian Therapeutics 的目标价从 32.00 美元上调至 36.00 美元，并给予该股票 “跑赢大盘” 的评级。Needham &amp; Company LLC 在 8 月 6 日的研究报告中将 Viridian Therapeutics 的目标价从 36.00 美元下调至 34.00 美元，并对该股票设定了 “买入” 评级。BTIG Research 在周二的研究报告中重新发布了 “买入” 评级，并对 Viridian Therapeutics 的股票设定了 61.00 美元的目标价。最后，Jefferies Financial Group 在 8 月 25 日的研究报告中开始覆盖 Viridian Therapeutics，给予 “买入” 评级和 44.00 美元的目标价。九位研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 38.22 美元。</p>
</div><p><strong>View Our Latest Research Report on Viridian Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Viridian Therapeutics 的最新研究报告</strong></p>
</div><h2>Insider Transactions at Viridian Therapeutics</h2>
<div class="lb-trans"><h2>Viridian Therapeutics 的内部交易</h2>
</div><p>In other news, Director Fairmount Funds Management Llc purchased 454,545 shares of the stock in a transaction dated Thursday, October 23rd. The stock was acquired at an average cost of $22.00 per share, for a total transaction of $9,999,990.00. Following the acquisition, the director owned 3,914,458 shares of the company's stock, valued at $86,118,076. The trade was a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 1.58% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事 Fairmount Funds Management Llc 在 10 月 23 日的交易中购买了 454,545 股该股票。该股票的平均购买成本为每股 22.00 美元，总交易额为 9,999,990.00 美元。收购后，该董事持有公司 3,914,458 股股票，价值 86,118,076 美元。此次交易使其持股增加了 13.14%。该收购在向 SEC 的备案中披露，相关信息可通过此链接访问。1.58% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Viridian Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Viridian Therapeutics 的看法</h2>
</div><p>Institutional investors have recently made changes to their positions in the company. Bessemer Group Inc. boosted its position in shares of Viridian Therapeutics by 947.7% in the 3rd quarter. Bessemer Group Inc. now owns 2,085 shares of the company's stock valued at $45,000 after purchasing an additional 1,886 shares during the period. Principal Financial Group Inc. boosted its position in shares of Viridian Therapeutics by 4.7% in the 3rd quarter. Principal Financial Group Inc. now owns 213,329 shares of the company's stock valued at $4,604,000 after purchasing an additional 9,493 shares during the period. AlphaQuest LLC lifted its stake in Viridian Therapeutics by 1,695.0% in the 3rd quarter. AlphaQuest LLC now owns 17,645 shares of the company's stock worth $381,000 after acquiring an additional 16,662 shares in the last quarter. Knights of Columbus Asset Advisors LLC lifted its stake in Viridian Therapeutics by 2.4% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 59,410 shares of the company's stock worth $1,282,000 after acquiring an additional 1,386 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd lifted its stake in Viridian Therapeutics by 430.3% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 64,594 shares of the company's stock worth $1,394,000 after acquiring an additional 52,414 shares in the last quarter.</p>
<div class="lb-trans"><p>机构投资者最近对该公司的持仓进行了调整。Bessemer Group Inc.在第三季度将其在 Viridian Therapeutics 的持仓增加了 947.7%。Bessemer Group Inc.目前持有 2,085 股该公司的股票，价值 45,000 美元，此前在该期间又购买了 1,886 股。Principal Financial Group Inc.在第三季度将其在 Viridian Therapeutics 的持仓增加了 4.7%。Principal Financial Group Inc.目前持有 213,329 股该公司的股票，价值 4,604,000 美元，此前又购买了 9,493 股。AlphaQuest LLC 在第三季度将其在 Viridian Therapeutics 的持仓增加了 1,695.0%。AlphaQuest LLC 目前持有 17,645 股该公司的股票，价值 381,000 美元，此前在上个季度又收购了 16,662 股。Knights of Columbus Asset Advisors LLC 在第三季度将其在 Viridian Therapeutics 的持仓增加了 2.4%。Knights of Columbus Asset Advisors LLC 目前持有 59,410 股该公司的股票，价值 1,282,000 美元，此前在上个季度又收购了 1,386 股。最后，Y Intercept Hong Kong Ltd 在第三季度将其在 Viridian Therapeutics 的持仓增加了 430.3%。Y Intercept Hong Kong Ltd 目前持有 64,594 股该公司的股票，价值 1,394,000 美元，此前在上个季度又收购了 52,414 股。</p>
</div><h2>Viridian Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Viridian Therapeutics 股票表现</h2>
</div><p>The firm has a 50 day moving average of $20.94 and a 200-day moving average of $17.34. The stock has a market capitalization of $2.25 billion, a PE ratio of -7.37 and a beta of 0.49. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.01 and a current ratio of 11.01.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 20.94 美元，200 日移动平均线为 17.34 美元。该股票的市值为 22.5 亿美元，市盈率为-7.37，贝塔值为 0.49。该公司的债务与股本比率为 0.04，速动比率为 11.01，流动比率为 11.01。</p>
</div><h2>About Viridian Therapeutics</h2>
<div class="lb-trans"><h2>关于 Viridian Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.</p>
<div class="lb-trans"><p>Viridian Therapeutics, Inc.是一家生物技术公司，致力于发现和开发严重和罕见疾病的治疗方案。该公司的产品管线包括 VRDN-001，一种针对类胰岛素生长因子-1 受体的单克隆抗体，目前正在进行治疗甲状腺眼病（TED）的三期临床试验；以及 VRDN-003，一种下一代 IGF-1R 人源化单克隆抗体，针对 IGF-1R 并结合半衰期延长技术用于治疗 TED。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Viridian Therapeutics</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>Dutch Bros Beats Earnings for 11th Consecutive Quarter</li>
<li>Investing In Automotive Stocks</li>
<li>From Dividends to Growth: Why These 3 Stocks Stand Out in 2025</li>
<li>How Investors Can Find the Best Cheap Dividend Stocks</li>
<li>AMD’s Price Pullback Equals Opportunity: The Big Gains Are Coming</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Viridian Therapeutics</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>Dutch Bros 连续第 11 个季度超预期盈利</li>
<li>投资汽车股票</li>
<li>从分红到增长：为什么这三只股票在 2025 年脱颖而出</li>
<li>投资者如何找到最佳的便宜分红股票</li>
<li>AMD 的价格回调意味着机会：大幅收益即将到来</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Viridian Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Viridian Therapeutics 吗？</h2>
</div><p>Before you consider Viridian Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Viridian Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Viridian Therapeutics 并不在名单上。</p>
</div><p>While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Viridian Therapeutics 目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Viridian Therapeutics（NASDAQ:VRDN）因盈利超预期而创下 12 个月新高